Laurence A. Turka's Net Worth
$18.2 Thousand
Who is Laurence A. Turka?
Laurence A. Turka does not have any significant net worth to report based on the numbers we have. This is based on reported shares in Rubius Therapeutics, Inc..
SEC CIK
Laurence A. Turka's CIK is 0001800952
Past Insider Trading and Trends
2022 was Laurence A. Turka's most active year for acquiring shares with 3 total transactions. Laurence A. Turka's most active month to acquire stocks was the month of December. 2023 was Laurence A. Turka's most active year for disposing of shares, totalling 3 transactions. Laurence A. Turka's most active month to dispose stocks was the month of December. 2020 saw Laurence A. Turka paying a total of $0.00 for 350,000 shares, this is the most they've acquired in one year. In 2022 Laurence A. Turka cashed out on 9,955 shares for a total of $16,544.24, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Rubius Therapeutics, Inc. (RUBY) Snapshot price: $0.057
Chief Scientific OfficerLaurence A. Turka owns 18,391 units of Common Stock which is worth $1,048.29. From 2020 to 2023 Laurence A. Turka acquired a total of 23,501 shares in Rubius Therapeutics, Inc., Laurence also disposed a total of 5,110 shares of Rubius Therapeutics, Inc. equalling to $17,166.56.
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +273.72% | 13.47K |
$0.24 | -$622.32 | 18.39K |
Jan 29 - Jan 31
| |||
Form 4
|
∞
| 4.92K |
$6.57 | -$16,544.24 | 4.92K |
Jan 29 - Feb 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 29
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 31
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||